Silver Sponsor
Catalent Biologics
Catalent Biologics is a global leader in development, manufacturing and analytical services for new biological entities, cell and gene therapies, biosimilars, sterile injectables, and antibody-drug conjugates. With over 20 years of proven expertise, Catalent Biologics has worked with 600+ mAbs and 80+ proteins, produced 16 biopharmaceutical drugs using GPEx® cell line development technology, and manufactured 45+ commercially approved products. Catalent Cell & Gene Therapy, a unit of Catalent Biologics, is an industry-leading technology, development and manufacturing partner for advanced therapeutics. Its comprehensive cell therapy portfolio includes a wide range of expertise across a variety of cell types including CAR-T, TCR, TILs, NKs, iPSCs, and MSCs. With deep expertise in viral vector development, scale-up and manufacturing for gene therapies, Catalent is a full-service partner for plasmid DNA, adeno-associated viral (AAV), lentiviral and other viral vectors, oncolytic viruses, and live virus vaccines. For more information, visit biologics.catalent.com
Associated Experts
Job Title: Director, Process Development Department
Job Title: Research Fellow
Associated Content
The Unique Challenges of Lipid Nanoparticle Development and Manufacturing
The use of lipid nanoparticles (LNPs) as non-viral delivery tools for messenger RNA (mRNA) helps alleviate the otherwise poor pharmacokinetics (PK) and in vivo instability of mRNA. However, LNP formulation development and manufacturing remains complex ... Continued
mRNA Development and Manufacturing: CMC Challenges and Solutions
The demand for mRNA-based vaccines and treatments has increased significantly, and the industry has been challenged to not only meet these needs, but also improve existing manufacturing processes and efficiencies. Current challenges with mRNA development ... Continued
mRNA: A New Option for Vaccines and Therapies
The use of mRNA for vaccines and therapeutics is being explored due to the advantages that the technology presents, and the promise of mRNA was demonstrated by COVID-19 vaccines, which provided a pathway for future ... Continued
Utilizing N-1 Perfusion to Increase Productivity and Intensify Processes
Join Claudia Berdugo, Ph.D., Director of Process Development at Catalent Biologics, where she discusses N-1 perfusion and how Catalent Biologics works toward process improvements for each client to enable them to move their pharmaceutical products forward with confidence....Continued